Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
News|Articles|March 9, 2024
Mood Disorders in Psychiatric Times
Author(s)Erin O'Brien
Take a look back at our recent coverage relating to our March content theme.
Advertisement
Advertisement
Related to this article
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
2
Interventional Options for TRD: ECT, TMS, and Esketamine
3
Vortioxetine's Effect on Cognitive Function in Older Adults With Major Depressive Disorder
4
Personalizing MDD Treatment: Evidence, Experience, and Patient Values
5